1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION 17
2.2 SCOPE OF THE STUDY 17
2.3 RESEARCH OBJECTIVE 17
2.4 MARKET STRUCTURE 18
2.5 ASSUMPTIONS & LIMITATIONS 19
3 RESEARCH METHODOLOGY
3.1 DATA MINING 20
3.2 SECONDARY RESEARCH 21
3.3 PRIMARY RESEARCH 22
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24
3.5 FORECASTING TECHNIQUES 25
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26
3.6.1 BOTTOM-UP APPROACH 27
3.6.2 TOP-DOWN APPROACH 27
3.7 DATA TRIANGULATION 28
3.8 VALIDATION 28
4 MARKET DYNAMICS
4.1 OVERVIEW 29
4.2 DRIVERS 30
4.2.1 RISING PREVALENCE OF INFLUENZA 30
4.2.2 INCREASING PUBLIC AND PRIVATE INITIATIVES FOR RESEARCH AND DEVELOPMENT 30
4.2.3 GROWING AWARENESS ABOUT INFLUENZA VACCINES 31
4.2.4 INCREASING PRODUCT LAUNCHES AND APPROVALS 31
4.3 RESTRAINTS 33
4.3.1 STRINGENT REGULATORY POLICIES 33
4.3.2 PRODUCT RECALLS AND CLINICAL TRIAL SUSPENSION 33
4.4 OPPORTUNITIES 34
4.4.1 INCREASING NUMBER OF CLINICAL TRIAL CANDIDATES 34
4.5 MARKET TRENDS 34
4.5.1 AMERICAS 34
4.5.2 EUROPE 35
4.5.3 ASIA-PACIFIC 35
4.5.4 MIDDLE EAST & AFRICA 35
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 36
5.1.1 BARGAINING POWER OF SUPPLIERS 36
5.1.2 BARGAINING POWER OF BUYERS 37
5.1.3 THREAT OF NEW ENTRANTS 37
5.1.4 THREAT OF SUBSTITUTES 37
5.1.5 INTENSITY OF RIVALRY 37
5.2 VALUE CHAIN ANALYSIS 38
5.2.1 R&D 39
5.2.2 MANUFACTURING 39
5.2.3 DISTRIBUTION 39
5.2.4 MARKETING & SALES 39
5.3 INVESTMENT SCENARIO 40
5.3.1 INVESTMENT OPPORTUNITY 40
5.3.2 INVESTMENTS BY MAJOR MARKET PLAYERS 41
5.4 PRODUCTION CAPACITY 41
6 GLOBAL INFLUENZA VACCINES MARKET BY INFLUENZA TYPE
6.1 OVERVIEW 42
6.2 SEASONAL 43
6.3 ZOONOTIC 44
7 GLOBAL INFLUENZA VACCINES MARKET BY MANUFACTURING TECHNOLOGY
7.1 OVERVIEW 45
7.2 EGG-BASED 46
7.3 CELL CULTURE-BASED 47
7.4 RECOMBINANT-BASED 48
8 GLOBAL INFLUENZA VACCINES MARKET BY VACCINE TYPE
8.1 OVERVIEW 49
8.2 QUADRIVALENT INFLUENZA VACCINES 50
8.3 TRIVALENT INFLUENZA VACCINES 51
9 GLOBAL INFLUENZA VACCINES MARKET BY END USER
9.1 OVERVIEW 52
9.2 HOSPITALS & CLINICS 53
9.3 RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES 54
9.4 OTHERS 54
10 GLOBAL INFLUENZA VACCINES MARKET BY REGION
10.1 OVERVIEW 55
10.2 AMERICAS 57
10.2.1 NORTH AMERICA 60
10.2.2 SOUTH AMERICA 62
10.3 EUROPE 64
10.3.1 UK 67
10.3.2 FRANCE 69
10.3.3 GERMANY 71
10.3.4 RUSSIA 73
10.3.5 ITALY 75
10.3.6 REST OF EUROPE 77
10.4 ASIA-PACIFIC 79
10.4.1 CHINA 82
10.4.2 INDIA 84
10.4.3 AUSTRALIA 86
10.4.4 NEW ZEALAND 88
10.4.5 REST OF ASIA-PACIFIC 90
10.5 MIDDLE EAST & AFRICA 92
10.5.1 SAUDI ARABIA 95
10.5.2 UAE 97
10.5.3 EGYPT 99
10.5.4 KUWAIT 101
10.5.5 SOUTH AFRICA 103
10.5.6 OMAN 105
10.5.7 REST OF MIDDLE EAST & AFRICA 107
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW 109
11.2 COMPANY SHARE ANALYSIS 109
11.3 COMPETITIVE BENCHMARKING 111
11.4 COMPETITOR DASHBOARD 112
11.5 MAJOR GROWTH STRATEGY IN THE GLOBAL INFLUENZA VACCINES MARKET 113
11.6 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL INFLUENZA VACCINES MARKET 114
11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 114
11.7.1 PRODUCT APPROVALS 115
11.7.2 EXPANSIONS & INVESTMENTS 115
11.7.3 ACQUISITIONS 116
11.7.4 COLLABORATIONS 116
12 COMPANY PROFILE
12.1 ASTRAZENECA 117
12.1.1 COMPANY OVERVIEW 117
12.1.2 FINANCIAL OVERVIEW 117
12.1.3 PRODUCTS/SERVICES OFFERED 118
12.1.4 KEY DEVELOPMENTS 118
12.1.5 SWOT ANALYSIS 119
12.1.6 KEY STRATEGIES 119
12.2 GLAXOSMITHKLINE PLC 120
12.2.1 COMPANY OVERVIEW 120
12.2.2 FINANCIAL OVERVIEW 120
12.2.3 PRODUCTS/SERVICES OFFERED 121
12.2.4 KEY DEVELOPMENTS 121
12.2.5 SWOT ANALYSIS 122
12.2.6 KEY STRATEGIES 122
12.3 SANOFI 123
12.3.1 COMPANY OVERVIEW 123
12.3.2 FINANCIAL OVERVIEW 123
12.3.3 PRODUCTS/SERVICES OFFERED 124
12.3.4 KEY DEVELOPMENTS 124
12.3.5 SWOT ANALYSIS 125
12.3.6 KEY STRATEGIES 125
12.4 ABBOTT LABORATORIES 126
12.4.1 COMPANY OVERVIEW 126
12.4.2 FINANCIAL OVERVIEW 126
12.4.3 PRODUCTS/SERVICES OFFERED 127
12.4.4 KEY DEVELOPMENTS 127
12.4.5 SWOT ANALYSIS 127
12.4.6 KEY STRATEGIES 128
12.5 SEQIRUS 129
12.5.1 COMPANY OVERVIEW 129
12.5.2 FINANCIAL OVERVIEW 130
12.5.3 PRODUCTS/SERVICES OFFERED 130
12.5.4 KEY DEVELOPMENTS 131
12.5.5 SWOT ANALYSIS 132
12.5.6 KEY STRATEGIES 132
12.6 HUALAN BIOLOGICAL ENGINEERING INC. 133
12.6.1 COMPANY OVERVIEW 133
12.6.2 FINANCIAL OVERVIEW 133
12.6.3 PRODUCTS/SERVICES OFFERED 133
12.6.4 KEY DEVELOPMENTS 133
12.6.5 SWOT ANALYSIS 134
12.6.6 KEY STRATEGIES 134
12.7 MITSUBISHI TANABE PHARMA 135
12.7.1 COMPANY OVERVIEW 135
12.7.2 FINANCIAL OVERVIEW 135
12.7.3 PRODUCTS/SERVICES OFFERED 136
12.7.4 KEY DEVELOPMENTS 136
12.7.5 SWOT ANALYSIS 137
12.7.6 KEY STRATEGIES 137
12.8 SERUM INSTITUTE OF INDIA PVT. LTD 138
12.8.1 COMPANY OVERVIEW 138
12.8.2 FINANCIAL OVERVIEW 138
12.8.3 PRODUCTS/SERVICES OFFERED 138
12.8.4 KEY DEVELOPMENTS 138
12.8.5 SWOT ANALYSIS 139
12.8.6 KEY STRATEGIES 139
12.9 MYLAN NV 140
12.9.1 COMPANY OVERVIEW 140
12.9.2 FINANCIAL OVERVIEW 140
12.9.3 PRODUCTS/SERVICES OFFERED 141
12.9.4 KEY DEVELOPMENTS 141
12.9.5 SWOT ANALYSIS 141
12.9.6 KEY STRATEGIES 142
13 APPENDIX
13.1 REFERENCES 143
13.2 RELATED REPORTS 143
14 LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS 19
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23
TABLE 3 GLOBAL INFLUENZA PRODUCTION CAPACITY, 2020 41
TABLE 4 GLOBAL INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 43
TABLE 5 GLOBAL INFLUENZA VACCINES MARKET, FOR SEASONAL, BY REGION, 2020–2027 (USD MILLION) 43
TABLE 6 GLOBAL INFLUENZA VACCINES MARKET, FOR ZOONOTIC, BY REGION, 2020–2027 (USD MILLION) 44
TABLE 7 GLOBAL INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 46
TABLE 8 GLOBAL INFLUENZA VACCINES MARKET, FOR EGG-BASED, BY REGION, 2020–2027 (USD MILLION) 46
TABLE 9 GLOBAL INFLUENZA VACCINES MARKET, FOR CELL CULTURE-BASED, BY REGION, 2020–2027 (USD MILLION) 47
TABLE 10 GLOBAL INFLUENZA VACCINES MARKET, FOR RECOMBINANT-BASED, BY REGION, 2020–2027 (USD MILLION) 48
TABLE 11 GLOBAL INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 50
TABLE 12 GLOBAL INFLUENZA VACCINES MARKET, FOR QUADRIVALENT INFLUENZA VACCINES, BY REGION, 2020–2027 (USD MILLION) 50
TABLE 13 GLOBAL INFLUENZA VACCINES MARKET, FOR TRIVALENT INFLUENZA VACCINES, BY REGION, 2020–2027 (USD MILLION) 51
TABLE 14 GLOBAL INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 53
TABLE 15 GLOBAL INFLUENZA VACCINES MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 53
TABLE 16 GLOBAL INFLUENZA VACCINES MARKET, FOR RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES, BY REGION,
2020–2027 (USD MILLION) 54
TABLE 17 GLOBAL INFLUENZA VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION) 56
TABLE 18 AMERICAS: INFLUENZA VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION) 58
TABLE 19 AMERICAS: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 58
TABLE 20 AMERICAS: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 58
TABLE 21 AMERICAS: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 59
TABLE 22 AMERICAS: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 59
TABLE 23 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 60
TABLE 24 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 60
TABLE 25 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 61
TABLE 26 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 61
TABLE 27 SOUTH AMERICA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 62
TABLE 28 SOUTH AMERICA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 62
TABLE 29 SOUTH AMERICA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 63
TABLE 30 SOUTH AMERICA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 63
TABLE 31 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
TABLE 32 EUROPE: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 65
TABLE 33 EUROPE: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 66
TABLE 34 EUROPE: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 66
TABLE 35 EUROPE: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 67
TABLE 36 UK: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 67
TABLE 37 UK: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 68
TABLE 38 UK: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 68
TABLE 39 UK: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 68
TABLE 40 FRANCE: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 69
TABLE 41 FRANCE: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 69
TABLE 42 FRANCE: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 70
TABLE 43 FRANCE: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 70
TABLE 44 GERMANY: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 71
TABLE 45 GERMANY: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 71
TABLE 46 GERMANY: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 72
TABLE 47 GERMANY: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 72
TABLE 48 RUSSIA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 73
TABLE 49 RUSSIA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 73
TABLE 50 RUSSIA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 74
TABLE 51 RUSSIA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 74
TABLE 52 ITALY: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 75
TABLE 53 ITALY: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 75
TABLE 54 ITALY: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 76
TABLE 55 ITALY: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 76
TABLE 56 REST OF EUROPE: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 77
TABLE 57 REST OF EUROPE: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 77
TABLE 58 REST OF EUROPE: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 78
TABLE 59 REST OF EUROPE: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 78
TABLE 60 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 61 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 80
TABLE 62 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 80
TABLE 63 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 81
TABLE 64 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 81
TABLE 65 CHINA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 82
TABLE 66 CHINA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 82
TABLE 67 CHINA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 83
TABLE 68 CHINA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 83
TABLE 69 INDIA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 84
TABLE 70 INDIA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 84
TABLE 71 INDIA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 85
TABLE 72 INDIA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 85
TABLE 73 AUSTRALIA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 86
TABLE 74 AUSTRALIA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 86
TABLE 75 AUSTRALIA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 87
TABLE 76 AUSTRALIA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 87
TABLE 77 NEW ZEALAND: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 88
TABLE 78 NEW ZEALAND: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 88
TABLE 79 NEW ZEALAND: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 89
TABLE 80 NEW ZEALAND: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 89
TABLE 81 REST OF ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 90
TABLE 82 REST OF ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 90
TABLE 83 REST OF ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 91
TABLE 84 REST OF ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 91
TABLE 85 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 86 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 93
TABLE 87 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 94
TABLE 88 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 94
TABLE 89 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 94
TABLE 90 SAUDI ARABIA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 95
TABLE 91 SAUDI ARABIA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 95
TABLE 92 SAUDI ARABIA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 96
TABLE 93 SAUDI ARABIA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 96
TABLE 94 UAE: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 97
TABLE 95 UAE: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 97
TABLE 96 UAE: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 98
TABLE 97 UAE: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 98
TABLE 98 EGYPT: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 99
TABLE 99 EGYPT: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 99
TABLE 100 EGYPT: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 100
TABLE 101 EGYPT: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 100
TABLE 102 KUWAIT: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 101
TABLE 103 KUWAIT: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 101
TABLE 104 KUWAIT: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 102
TABLE 105 KUWAIT: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 102
TABLE 106 SOUTH AFRICA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 103
TABLE 107 SOUTH AFRICA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 103
TABLE 108 SOUTH AFRICA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 104
TABLE 109 SOUTH AFRICA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 104
TABLE 110 OMAN: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 105
TABLE 111 OMAN: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 105
TABLE 112 OMAN: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 106
TABLE 113 OMAN: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 106
TABLE 114 REST OF MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 107
TABLE 115 REST OF MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY,
2020–2027 (USD MILLION) 107
TABLE 116 REST OF MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 108
TABLE 117 REST OF MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 108
TABLE 118 THE MOST ACTIVE PLAYER IN THE GLOBAL INFLUENZA VACCINES MARKET 114
TABLE 119 PRODUCT APPROVALS 115
TABLE 120 EXPANSIONS 115
TABLE 121 INVESTMENTS 116
TABLE 122 ACQUISITIONS 116
TABLE 123 COLLABORATIONS 116
TABLE 124 ASTRAZENECA: PRODUCTS/SERVICES OFFERED 118
TABLE 125 ASTRAZENECA: KEY DEVELOPMENTS 118
TABLE 126 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 121
TABLE 127 GLAXOSMITHKLINE PLC: KEY DEVELOPMENTS 121
TABLE 128 SANOFI: PRODUCTS/SERVICES OFFERED 124
TABLE 129 SANOFI: KEY DEVELOPMENTS 124
TABLE 130 ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED 127
TABLE 131 ABBOTT LABORATORIES: KEY DEVELOPMENTS 127
TABLE 132 SEQIRUS: PRODUCTS/SERVICES OFFERED 130
TABLE 133 SEQIRUS: KEY DEVELOPMENTS 131
TABLE 134 HUALAN BIOLOGICAL ENGINEERING INC.: PRODUCTS/SERVICES OFFERED 133
TABLE 135 HUALAN BIOLOGICAL ENGINEERING INC.: KEY DEVELOPMENTS 133
TABLE 136 MITSUBISHI TANABE PHARMA: PRODUCTS/SERVICES OFFERED 136
TABLE 137 MITSUBISHI TANABE PHARMA: KEY DEVELOPMENTS 136
TABLE 138 SERUM INSTITUTE OF INDIA PVT. LTD: PRODUCTS/SERVICES OFFERED 138
TABLE 139 MYLAN NV: PRODUCTS/SERVICES OFFERED 141
TABLE 140 MYLAN NV: KEY DEVELOPMENTS 141
15 LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 16
FIGURE 2 GLOBAL INFLUENZA VACCINES MARKET: STRUCTURE 18
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 26
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL INFLUENZA VACCINES MARKET 29
FIGURE 5 DRIVER IMPACT ANALYSIS 32
FIGURE 6 RESTRAINT IMPACT ANALYSIS 33
FIGURE 7 PORTER’S FIVE FORCES ANALYSIS: GLOBAL INFLUENZA VACCINES MARKET 36
FIGURE 8 VALUE CHAIN ANALYSIS OF THE GLOBAL INFLUENZA VACCINES MARKET 38
FIGURE 9 GLOBAL INFLUENZA VACCINES MARKET SHARE, BY INFLUENZA TYPE, 2020 (%) 42
FIGURE 10 GLOBAL INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020 AND 2027 (USD MILLION) 42
FIGURE 11 GLOBAL INFLUENZA VACCINES MARKET SHARE, BY MANUFACTURING TECHNOLOGY, 2020 (%) 45
FIGURE 12 GLOBAL INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020 AND 2027 (USD MILLION) 45
FIGURE 13 GLOBAL INFLUENZA VACCINES MARKET SHARE, BY VACCINE TYPE, 2020 (%) 49
FIGURE 14 GLOBAL INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020 AND 2027 (USD MILLION) 49
FIGURE 15 GLOBAL INFLUENZA VACCINES MARKET SHARE, BY END USER, 2020 (%) 52
FIGURE 16 GLOBAL INFLUENZA VACCINES MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 52
FIGURE 17 GLOBAL INFLUENZA VACCINES MARKET SHARE, BY REGION, 2020 (%) 55
FIGURE 18 GLOBAL INFLUENZA VACCINES MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 55
FIGURE 19 AMERICAS: INFLUENZA VACCINES MARKET, BY REGION, 2020 AND 2027 57
FIGURE 20 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020 AND 2027 64
FIGURE 21 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020 AND 2027 79
FIGURE 22 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020 AND 2027 92
FIGURE 23 GLOBAL INFLUENZA VACCINES MARKET SHARE ANALYSIS, 2020 (%) 109
FIGURE 24 BENCHMARKING OF MAJOR COMPETITORS 111
FIGURE 25 COMPETITOR DASHBOARD: GLOBAL INFLUENZA VACCINES MARKET 112
FIGURE 26 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE INFLUENZA VACCINES MARKET 113
FIGURE 27 GLOBAL INFLUENZA VACCINE MARKET, KEY DEVELOPMENTS & GROWTH STRATEGIES (%) 114
FIGURE 28 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 117
FIGURE 29 ASTRAZENECA: SWOT ANALYSIS 119
FIGURE 30 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 120
FIGURE 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 122
FIGURE 32 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 123
FIGURE 33 SANOFI: SWOT ANALYSIS 125
FIGURE 34 ABBOTT LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT 126
FIGURE 35 ABBOTT LABORATORIES: SWOT ANALYSIS 127
FIGURE 36 CSL LIMITED: FINANCIAL OVERVIEW SNAPSHOT 130
FIGURE 37 SEQIRUS: SWOT ANALYSIS 132
FIGURE 38 HUALAN BIOLOGICAL ENGINEERING INC.: SWOT ANALYSIS 134
FIGURE 39 MITSUBISHI TANABE PHARMA: FINANCIAL OVERVIEW SNAPSHOT 135
FIGURE 40 MITSUBISHI TANABE PHARMA: SWOT ANALYSIS 137
FIGURE 41 SERUM INSTITUTE OF INDIA PVT. LTD: SWOT ANALYSIS 139
FIGURE 42 MYLAN NV: FINANCIAL OVERVIEW SNAPSHOT 140
FIGURE 43 MYLAN NV: SWOT ANALYSIS 141
